ImmusanT goes on hiring spree ahead of phase 2 celiac vaccine trial

ImmusanT is planning to launch a phase 2 trial of its lead candidate, celiac disease vaccine Nexvax2, in the third quarter of this year. Nexvax2 reprograms T cells responsible for triggering an inflammatory response following exposure to gluten. (Pixabay)

ImmusanT is boosting its senior staff, bringing on Daiichi Sankyo’s SVP for internal medicine therapeutics, Ken Truitt, M.D., as its new chief medical officer, while also hiring new VPs in clinical operations and program management, as well as a new finance director, as it looks to advance development of its treatments for celiac disease and Type 1 diabetes.

Truitt previously served as the Japanese pharma's global head of translational medicine and clinical pharmacology, and as VP of clinical development. Before that, he was director of clinical research at Merck’s pulmonary-immunology division.

“Ken brings years of experience developing drug candidates through all stages of development, including preclinical development, and running all phases of clinical trial advancement through to submission of new drug applications,” ImmusanT CEO Leslie Williams said in a statement (PDF).

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Cambridge, Massachusetts-based ImmusanT also hired (PDF) Kristin Neff as VP of clinical operations and project management; Joyce Pinkham as VP of program management; and Jonathan Yeadon as finance director.

RELATED: ImmusanT's celiac disease immunotherapy passes first clinical test

Neff joins from InVivo Therapeutics, where she was VP of clinical operations and project management, and helped lead development of a medical device to treat acute spinal cord injury.

Pinkham, former VP of program and alliance management at Juniper Pharmaceuticals, will begin work June 11. She has also held senior program and portfolio management positions at Cubist Pharmaceuticals and Genzyme.

Yeadon, meanwhile, served as director of finance at Wolfe Laboratories and brings over 12 years of experience overseeing finance operations in the life sciences.

The hiring spree comes as the biotech expects to launch a midstage test of its lead celiac vaccine candidate, Nexvax2, in the third quarter, with additional plans to grow its epitope-specific immuno-therapy platform for new treatments against autoimmune diseases, including Type 1 diabetes.

Late last year, ImmusanT brought in $40 million in series C financing to support the trial. Nexvax2 reprograms T cells responsible for the symptoms of celiac disease to stop triggering a pro-inflammatory response following exposure to gluten.

Suggested Articles

J&J's DePuy Synthes division has launched a new fixation system to expand treatment options for patients with frail bones in the neck and upper back.

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Tokyo-based Heartseed has raised 2.8 billion yen, or about $26 million U.S., to help develop its stem cell-based treatment for heart failure.